Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART

CompletedOBSERVATIONAL
Enrollment

12,011

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
HIVInfant Exposure to Efavirenz
Trial Locations (1)

Unknown

UNC Project Malawi, Lilongwe

All Listed Sponsors
collaborator

Ministry of Health and Population, Malawi

OTHER_GOV

collaborator

University of North Carolina

OTHER

collaborator

Lighthouse Trust

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02249962 - Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART | Biotech Hunter | Biotech Hunter